Zacks Investment Research upgraded shares of Bionomics (OTCMKTS:BNOEF) from a sell rating to a hold rating in a report issued on Friday morning.
According to Zacks, “Bionomics Limited is a biopharmaceutical company. It discovers and develops drug for the treatment of central nervous system disorders and cancer. The companys product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers’s disease; BNC101, a monoclonal antibody that targets cancer stem cells and BNC105, a novel compound to disrupt the blood vessels. It operates primarily in Australia, France and the United States. Bionomics Limited is based in Thebarton, Australia. “
Separately, ValuEngine upgraded shares of Bionomics from a hold rating to a buy rating in a research note on Thursday, November 1st.
Shares of OTCMKTS BNOEF remained flat at $$0.09 during mid-day trading on Friday. 123,000 shares of the stock were exchanged, compared to its average volume of 72,805. Bionomics has a one year low of $0.09 and a one year high of $0.70.
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments.
Further Reading: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.